Результати пошуку - Árpád Illès

Уточнити результати
  1. 1
    Treatment-Emergent Resistance to Asciminib in Chronic Myeloid Leukemia Patients Due to Myristoyl-Binding Pocket-Mutant of BCR::ABL1/A337V Can Be Effectively Overcome with Dasatinib Treatment

    Treatment-Emergent Resistance to Asciminib in Chronic Myeloid Leukemia Patients Due to Myristoyl-Binding Pocket-Mutant of BCR::ABL1/A337V Can Be Effectively Overcome with Dasatinib... за авторством Péter Batár, Gabriella Mezei, Árpád Illés

    Опубліковано 2025
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  2. 2
    The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors

    The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors за авторством Ádám Jóna, Noor M. Khaskhely, Daniela Buglio, Jessica A. Shafer, Enrico Derenzini, Catherine M. Bollard, L. Jeffrey Medeiros, Árpád Illés, Yuan Ji, Anas Younes

    Опубліковано 2011
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  3. 3
    Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b

    Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b за авторством Jean‐Jacques Kiladjian, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva, Miklós Egyed, Petr Ďulíček, Árpád Illés, Halyna Pylypenko, Lylia Sivcheva, Jiřı́ Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans Carl Hasselbalch, Róbert Královics, Heinz Gisslinger, Jean‐Jacques Kiladjian, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva, Miklós Egyed, Petr Ďulíček, Árpád Illés, Halyna Pylypenko, Lylia Sivcheva, Jiřı́ Mayer, Vera Yablokova, Heinz Gisslinger

    Опубліковано 2022
    Отримати повний текст Отримати повний текст
    Carta
    Додати у Вибране
    Збережено в:
  4. 4
    Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study

    Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study за авторством Vincent Ribrag, Won Seog Kim, Réda Bouabdallah, Soon Thye Lim, Bertrand Coiffier, Árpád Illés, Bernard Lemieux, Martin J.S. Dyer, Fritz Offner, Zakia Felloussi, Ioana Kloos, Ying Luan, Remus Vezan, Thorsten Graef, Franck Morschhauser

    Опубліковано 2017
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  5. 5
    Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results

    Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results за авторством Paolo Ghia, Andrzej Pluta, Małgorzata Wach, Daniel Lysák, Martin Šimkovič, Iryna Kriachok, Árpád Illés, Javier de la Serna, Sean Dolan, Philip Campbell, Gerardo Musuraca, Abraham Jacob, Eric J. Avery, Jae Hoon Lee, Ganna Usenko, Min Hui Wang, Ting Yu, Wojciech Jurczak

    Опубліковано 2022
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  6. 6
    Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment

    Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment за авторством Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva, Miklós Egyed, Petr Ďulíček, Árpád Illés, Halyna Pylypenko, Lylia Sivcheva, Jiřı́ Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans Carl Hasselbalch, Róbert Královics, Jean‐Jacques Kiladjian, Heinz Gisslinger, Jean‐Jacques Kiladjian

    Опубліковано 2023
    Отримати повний текст Отримати повний текст
    Carta
    Додати у Вибране
    Збережено в:
  7. 7
    ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

    ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia за авторством Paolo Ghia, Andrzej Pluta, Małgorzata Wach, Daniel Lysák, Tomáš Kozák, Martin Šimkovič, Polina Kaplan, Iryna Kraychok, Árpád Illés, Javier de la Serna, Sean Dolan, Phillip L. Campbell, Gerardo Musuraca, Abraham Jacob, Eric J. Avery, Jae Hoon Lee, Wei Liang, Priti Patel, Cheng S. Quah, Wojciech Jurczak

    Опубліковано 2020
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  8. 8
    Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy

    Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy за авторством David J. Straus, Graham P. Collins, Jan Walewski, Pier Luigi Zinzani, Andrew Grigg, Anna Sureda, Árpád Illés, Tae Min Kim, Sergey Alekseev, Lena Specht, Valéria Buccheri, Anas Younes, Joseph M. Connors, Andres Forero‐Torres, Keenan Fenton, Ashish Gautam, Indra Purevjal, Rachael Liu, Andrea Gallamini

    Опубліковано 2020
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  9. 9
    Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials

    Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials за авторством Jean‐Jacques Kiladjian, Alessandro M. Vannucchi, Aaron T. Gerds, Vikas Gupta, Srđan Verstovšek, Miklós Egyed, Uwe Platzbecker, Jiřı́ Mayer, Sebastian Grosicki, Árpád Illés, T Woźny, Stephen T. Oh, Donal P. McLornan, Ilya Kirgner, Sung‐Soo Yoon, Claire Harrison, Barbara Klencke, Mei Huang, Jun Kawashima, Ruben A. Mesa

    Опубліковано 2023
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  10. 10
    Mutational profile of previously treated chronic lymphocytic leukemia patients progressing on acalabrutinib or ibrutinib

    Mutational profile of previously treated chronic lymphocytic leukemia patients progressing on acalabrutinib or ibrutinib за авторством Jennifer A. Woyach, Daniel Jones, Wojciech Jurczak, Tadeusz Robak, Árpád Illés, Arnon P. Kater, Paolo Ghia, John C. Byrd, John F. Seymour, Susan K. De Long, Nehad Mohamed, Samon Benrashid, Tzung-Huei Lai, Gary De Jesus, Richard Lai, Gerjan de Bruin, Simon Rule, Veerendra Munugalavadla

    Опубліковано 2024
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  11. 11
    Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine

    Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine за авторством Keith W. Pratz, Brian A. Jonas, Vinod Pullarkat, Christian Récher, Andre C. Schuh, Michael J. Thirman, Jacqueline S. Garcia, Courtney D. DiNardo, Vladimir Vorobyev, Nicola Fracchiolla, Su‐Peng Yeh, Jun Ho Jang, Muhi̇t Özcan, Kazuhito Yamamoto, Árpád Illés, Ying Zhou, Monique Dail, Brenda Chyla, Jalaja Potluri, Hartmut Döhner

    Опубліковано 2021
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  12. 12
    Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial

    Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomis... за авторством Andrew D. Zelenetz, Jacqueline C. Barrientos, Jennifer R Brown, Bertrand Coiffier, Julio Delgado, Miklós Egyed, Paolo Ghia, Árpád Illés, Wojciech Jurczak, Paula Marlton, Marco Montillo, Franck Morschhauser, Alexander Pristupa, Tadeusz Robak, Jeff P Sharman, David Simpson, Lukáš Smolej, Eugen Tausch, Adeboye H Adewoye, Lyndah Dreiling, Yeonhee Kim, Stephan Stilgenbauer, Peter Hillmen

    Опубліковано 2017
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  13. 13
    A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts

    A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts за авторством Guillermo Garcia‐Manero, Mikkael A. Sekeres, Miklós Egyed, Massimo Breccia, Carlos Graux, Jamie Cavenagh, H Salman, Árpád Illés, Pierre Fenaux, Daniel J. DeAngelo, Reinhard Stauder, Karen Yee, Nancy Zhu, Je‐Hwan Lee, David Valcárcel, Alan Macwhannell, Z Borbényi, Lucien Gazi, Suddhasatta Acharyya, Susan Ide, Mahtab Marker, Oliver G. Ottmann

    Опубліковано 2017
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  14. 14
    The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

    The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL за авторством Ian W. Flinn, Peter Hillmen, Marco Montillo, Zsolt Nagy, Árpád Illés, Gabriel Étienne, Julio Delgado, Bryone J. Kuss, Constantine S. Tam, Zoltán Gasztonyi, Fritz Offner, Scott D. Lunin, F. Bosch, Matthew S. Davids, Nicole Lamanna, Ulrich Jaeger, Paolo Ghia, Florence Cymbalista, Craig A. Portell, Alan P Skarbnik, Amanda F. Cashen, David T. Weaver, Virginia Kelly, Barry Turnbull, Stephan Stilgenbauer

    Опубліковано 2018
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  15. 15
    A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma

    A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma за авторством Franck Morschhauser, Pierre Feugier, Ian W. Flinn, Robin Gasiorowski, Richard Greil, Árpád Illés, Nathalie A. Johnson, Jean-François Larouche, Pieternella J. Lugtenburg, Caterina Patti, Gilles Salles, Marek Trněný, Sven de Vos, Farheen Mir, Divya Samineni, Su Y. Kim, Yanwen Jiang, Elizabeth A. Punnoose, Arijit Sinha, Emma Clark, Nathalie Spielewoy, Kathryn Humphrey, Alexandra Bazeos, Andrew D. Zelenetz

    Опубліковано 2020
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  16. 16
    Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

    Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study за авторством David J. Straus, Monika Długosz‐Danecka, Sergey Alekseev, Árpád Illés, Marco Picardi, Ewa Lech‐Marańda, Tatyana Feldman, Piotr Smolewski, Kerry J. Savage, Nancy L. Bartlett, Jan Walewski, Radhakrishnan Ramchandren, Pier Luigi Zinzani, Martin Hutchings, Joseph M. Connors, John Radford, Javier Muñoz, Won Seog Kim, Ranjana H. Advani, Stephen M. Ansell, Anas Younes, Harry Miao, Rachael Liu, Keenan Fenton, Andres Forero‐Torres, Andrea Gallamini

    Опубліковано 2020
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  17. 17
    Efficacy and Safety of the Panobinostat-Bortezomib-Dexamethasone Combination in Relapsed or Relapsed/Refractory Multiple Myeloma: Results from the Randomized Panorama 3 Study

    Efficacy and Safety of the Panobinostat-Bortezomib-Dexamethasone Combination in Relapsed or Relapsed/Refractory Multiple Myeloma: Results from the Randomized Panorama 3 Study за авторством Jacob P. Laubach, Fredrik Schjesvold, Mário Mariz, Meletios Α. Dimopoulos, Ewa Lech‐Marańda, Ivan Špıčka, Vânia Hungria, Tatiana Shelekhova, André Abdo, Lutz Jacobasch, Chantana Polprasert, Roman Hájek, Árpád Illès, Tomasz Wróbel, Anna Sureda, Meral Beksaç, Iara Gonçalves, Joan Bladé Creixenti, S. Vincent Rajkumar, Ajai Chari, Sagar Lonial, Andrew Spencer, Pierre Maison‐Blanche, Philippe Moreau, Paul G. Richardson, Jesús F. San Miguel

    Опубліковано 2020
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  18. 18
    Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial

    Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial за авторством John C. Byrd, Peter Hillmen, Paolo Ghia, Arnon P. Kater, Chanan-Khan Asher, Richard R. Furman, Susan O’Brien, Mustafa Nuri Yenerel, Árpád Illés, Neil E. Kay, José A. García‐Marco, Anthony R. Mato, Javier Pinilla‐Ibarz, John F. Seymour, Stéphane Leprêtre, Stephan Stilgenbauer, Tadeusz Robak, Wayne Rothbaum, Raquel Izumi, Ahmed Hamdy, Priti Patel, Kara Higgins, Sophia Sohoni, Wojciech Jurczak

    Опубліковано 2021
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  19. 19
    Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

    Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma за авторством Joseph M. Connors, Wojciech Jurczak, David J. Straus, Stephen M. Ansell, Won S. Kim, Andrea Gallamini, Anas Younes, Sergey Alekseev, Árpád Illés, Marco Picardi, Ewa Lech‐Marańda, Yasuhiro Oki, Tatyana Feldman, Piotr Smolewski, Kerry J. Savage, Nancy L. Bartlett, Jan Walewski, Robert Chen, Radhakrishnan Ramchandren, Pier Luigi Zinzani, David Cunningham, András Rosta, Neil C. Josephson, Eric Song, Jessica Sachs, Rachael Liu, Hina Jolin, Dirk Huebner, John Radford

    Опубліковано 2017
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  20. 20
    Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

    Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia за авторством Courtney D. DiNardo, Brian A. Jonas, Vinod Pullarkat, Michael J. Thirman, Jacqueline S. Garcia, Andrew H. Wei, Marina Konopleva, Hartmut Döhner, Anthony Letai, Pierre Fenaux, Elizabeth A. Koller, Violaine Havelange, Brian Leber, Jordi Esteve, Jianxiang Wang, Vlatko Pejša, Roman Hájek, Kimmo Porkka, Árpád Illés, David Lavie, Roberto M. Lemoli, Kazuhito Yamamoto, Sung‐Soo Yoon, Jun‐Ho Jang, Su‐Peng Yeh, Mehmet Turgut, Wan‐Jen Hong, Ying Zhou, Jalaja Potluri, Keith W. Pratz

    Опубліковано 2020
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:

Інструменти для пошуку: